Clinical Trials Browser

OTHER × Drug Therapy × Breast × Clear all

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Phase NA Active not recruiting

Breast Neoplasms

NCT04703244 2026-03-03

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07372079 2026-01-28

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Phase 2 Not yet recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06195709 2025-12-18

ECLECTIC

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03676257 2025-12-10

Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

20,033 enrolled 9 charts

Breast Neoplasms

NCT05076682 2025-12-03

Renaissance

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06731140 2025-11-17

Resilire

Phase 2 Recruiting

HER2 Negative Breast Cancer

NCT07152938 2025-09-15

AVR-CHEMO

Phase NA Completed

BreastGastrointestinalLymphoidPlasma cell

Agnosia, Anxiety Disorders, Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07137793 2025-08-22

PTX / BC

Phase 2 Recruiting

Breast Neoplasms

NCT07127315 2025-08-17

Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy

Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06027541 2025-08-03

Young Patients With Early Breast Cancer

Active not recruiting

Breast Cancer Female

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07096180 2025-07-31

Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

Breast Neoplasms

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

Triple Negative Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase 2 Completed

HER2-negative Metastatic Breast Cancer

NCT06678048 2025-06-06

Arsenous Acid for Refractory Triple-Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06990347 2025-05-25

A Study on the Efficacy and Safety of IPyC for HER2+ MBC

Breast Neoplasms

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06828614 2025-02-14

Barriers to Therapeutic Exercise in Breast Cancer Patients Before, During, and After Chemotherapy

Enrolling by invitation

Breast Neoplasms, Fatigue, Motor Activity

NCT06642441 2025-01-17

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Phase NA Recruiting

Breast Neoplasms

NCT06727357 2024-12-10

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

Phase 2 Active not recruiting

Breast Neoplasms

NCT03227328 2024-11-07

KENDO

Phase 2 Completed

Breast Neoplasms

NCT03393741 2024-06-25

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Breast Neoplasms

NCT06438055 2024-05-31

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

Phase NA Not yet recruiting

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

Breast Neoplasms

NCT06341621 2024-04-10

Rainbow

Phase 3 Recruiting

Breast Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06165900 2024-01-03

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Phase 2 Recruiting

Breast Neoplasms

NCT05862610 2023-07-24

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT02679040 2023-07-03

HIST-RIC

Phase 2 Unknown

Breast Neoplasms

NCT05916755 2023-06-23

PORTRAIT

Triple Negative Breast Neoplasms

NCT05840068 2023-05-03

IGF Level in Breast Cancer Patients Treated With Metformin

Phase 4 Completed

Breast Neoplasms

NCT00004935 2023-04-18

Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

Phase 3 Terminated

Breast Neoplasms

NCT04435964 2023-03-24

G-DEFINER

BreastDermatologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Urogenital Neoplasms

NCT05680194 2023-01-11

EEBC

Breast Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast Neoplasms

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

Breast Neoplasms